22h
GlobalData on MSNVivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results